Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/22/2025 07:25 PDT] ABOS Expected to Trade Down After Bearish Patterns Develop
• [04/09/2025 13:58 PDT] Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), Up By 100% ($0.97) From $0.97 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/09/2025 07:19 PDT] ABOS Expected to Trade Up After Bullish Patterns Develop
• [04/08/2025 07:58 PDT] ABOS Expected to Trade Up After Bullish Patterns Develop
• [04/03/2025 10:29 PDT] Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), Down By 100% ($1.26) From $1.255 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions